NEUP — NEUPHORIA THERAPEUTICS INC (Healthcare >> Biotechnology)
NEUP FAQ
What is NEUP's P/E ratio?
NEUPHORIA THERAPEUTICS INC (NEUP) currently trades at a P/E ratio of 8.55.
What is NEUP's ROE?
NEUPHORIA THERAPEUTICS INC reports a Return on Equity (ROE) of -93.64%.
What is NEUP's dividend yield?
NEUPHORIA THERAPEUTICS INC offers a dividend yield of 0.00%.
What is NEUP's Deepscope Quality Score?
Deepscope rates NEUP's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy NEUP?
Deepscope's AI Timing Score for NEUP is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does NEUP belong to?
NEUPHORIA THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 4.49
Price
0.07
(1.58%)
Day Change
|
|
|---|
NEUP Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 38) và Thời điểm mua ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
Lịch sử ROE tương đối thấp
ROE đang giảm đáng kể
ROA quá thấp so với ROE
Tăng trưởng ROA hiện tại đang dưới mức tiêu chí của chúng tôi.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
Lịch sử Biên lợi nhuận ròng tương đối thấp.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt lắm , Sức khỏe tài chính Không tốt lắm , và khả năng kiếm lợi nhuận Khá , ...
| Yếu tố Chất lượng |
|
51% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 75 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 4.49 |
| PBV / Sector |
0.81 / 4.79
GREAT
|
| Earning Per Share | -5.18 |
| PE / Sector |
8.55 / 18.05
GREAT
|
| PEG or PE/Growth / Sector |
-106.93 / 0.62
|
| Average 1M Daily Value |
0.33 M
GREAT
|
| Average 1W Daily Value |
0.31 M
GREAT
|
| Yếu tố Kỹ thuật |
|
28% |
| Sức khỏe tài chính |
|
50% |
| Khả năng kiếm lợi nhuận |
|
60% |
| Lợi tức cho nhà đầu tư |
|
4% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-12 09:43:54 |
| Symbol | NEUP |
| Name | NEUPHORIA THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 5.40 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 23.89 / 9,010.81 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 100 Summit Drive, Burlington, MA, United States, 01803
Phone: 781 439 5551
Website: https://www.neuphoriatx.com
Sector: Healthcare >> Biotechnology
Description: Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for the treatment of cancer. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; and Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google